-
EP3952900
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3952900
| EP3952900 - FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 18.04.2024 Database last updated on 22.05.2024 | |
| Former | Request for examination was made Status updated on 14.01.2022 | ||
| Former | The international publication has been made Status updated on 16.10.2020 | ||
| Former | unknown Status updated on 13.05.2020 | Most recent event Tooltip | 19.04.2024 | First examination report | Applicant(s) | For all designated states R.P. Scherer Technologies, LLC 112 North Curry Street Carson City NV 89703 / US | For all designated states Pfizer Ireland Pharmaceuticals Operations Support Group Ringaskiddy Cork / IE | [2023/10] |
| Former [2022/07] | For all designated states R.P. Scherer Technologies, LLC 112 North Curry Street Carson City NV 89703 / US | ||
| For all designated states Biohaven Pharmaceutical Holding Company Ltd. 215 Church Street New Haven, CT 06510 / US | Inventor(s) | 01 /
PLASSAT, Vincent 9 rue de l'Orme aux Loups 91590 La Ferté Alais / FR | 02 /
HILBOLD, Benoit 26 rue de Saales 67300 Schiltigheim / FR | 03 /
GALUS, Aurélia 138 rue de la République 67720 Weyersheim / FR | 04 /
POINTEAUX, Thomas 7 rue des Tulipes 67116 Reichstett / FR | 05 /
MEISSONNIER, Julien 4 rue Saint Nabor 67460 Souffelweyersheim / FR | 06 /
DUBOWCHIK, Gene M. c/o Biohaven Pharmaceutical Holding Company Ltd. 215 Church Street New Haven, Connecticut 06510 / US | 07 /
CONWAY, Charles M. c/o Biohaven Pharmaceutical Holding Company Ltd. 215 Church Street New Haven, Connecticut 06510 / US | 08 /
KUMAR, Rajesh New Haven, Connecticut 06510 / US | [2023/18] |
| Former [2022/07] | 01 /
PLASSAT, Vincent 9 rue de l'Orme aux Loups 91590 La Ferté Alais / FR | ||
| 02 /
HILBOLD, Benoit 26 rue de Saales 67300 Schiltigheim / FR | |||
| 03 /
GALUS, Aurélia 138 rue de la République 67720 Weyersheim / FR | |||
| 04 /
POINTEAUX, Thomas 7 rue des Tulipes 67116 Reichstett / FR | |||
| 05 /
MEISSONNIER, Julien 4 rue Saint Nabor 67460 Souffelweyersheim / FR | |||
| 06 /
DUBOWCHIK, Gene M. c/o Biohaven Pharmaceutical Holding Company Ltd. 215 Church Street New Haven, Connecticut 06510 / US | |||
| 07 /
CONWAY, Charles M. c/o Biohaven Pharmaceutical Holding Company Ltd. 215 Church Street New Haven, Connecticut 06510 / US | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2022/07] | Application number, filing date | 20723680.3 | 10.04.2020 | [2022/07] | WO2020US27800 | Priority number, date | US201962832508P | 11.04.2019 Original published format: US 201962832508 P | [2022/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020210722 | Date: | 15.10.2020 | Language: | EN | [2020/42] | Type: | A1 Application with search report | No.: | EP3952900 | Date: | 16.02.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.10.2020 takes the place of the publication of the European patent application. | [2022/07] | Search report(s) | International search report - published on: | EP | 15.10.2020 | Classification | IPC: | A61K38/00, A61K9/08, A61K9/10, A61K47/14, A61K31/4545 | [2022/07] | CPC: |
A61K9/08 (EP,IL,KR);
A61K47/14 (EP,IL,KR,US);
A61K9/10 (EP,IL,KR);
A61K31/496 (US);
A61K38/00 (EP,IL,KR);
A61K38/03 (IL,US);
A61K39/39591 (EP,IL,KR);
A61K47/26 (US);
A61K47/34 (IL,US);
C07K16/18 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/07] | Extension states | BA | 10.11.2021 | ME | 10.11.2021 | Validation states | MD | 10.11.2021 | Title | German: | FORMULIERUNG ZUR ORALEN VERABREICHUNG VON PROTEINEN, PEPTIDEN UND KLEINEN MOLEKÜLEN MIT SCHLECHTER PERMEABILITÄT | [2022/07] | English: | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | [2022/07] | French: | FORMULATION POUR L'ADMINISTRATION PAR VOIE ORALE DE PROTÉINES, DE PEPTIDES ET DE PETITES MOLÉCULES À FAIBLE PERMÉABILITÉ | [2022/07] | Entry into regional phase | 10.11.2021 | National basic fee paid | 10.11.2021 | Designation fee(s) paid | 10.11.2021 | Examination fee paid | Examination procedure | 10.11.2021 | Examination requested [2022/07] | 10.11.2021 | Date on which the examining division has become responsible | 06.06.2022 | Amendment by applicant (claims and/or description) | 17.04.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 14.03.2022 | Renewal fee patent year 03 | 21.03.2023 | Renewal fee patent year 04 | 18.03.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]US2005079145 (CONSTANTINIDES PANAYIOTIS P [US], et al) [Y] 1-20 * paragraph [0107] * * paragraph [0125] *; | [Y]US2017037117 (DILLIN ANDREW [US], et al) [Y] 1-20 * paragraphs [0005] - [0018] * * paragraph [0334] - paragraph [0363] *; | [A] - TEPPER STEWART J ED - AGUGGIA MARCO, "CGRP and headache: a brief review", NEUROLOGICAL SCIENCES (TESTO STAMPATO), SPRINGER VERLAG, MILAN, IT, vol. 40, no. 1, doi:10.1007/S10072-019-03769-8, ISSN 1590-1874, (20190305), pages 99 - 105, (20190305), XP036780416 [A] 1-20 * page 5103, paragraph 5 * DOI: http://dx.doi.org/10.1007/s10072-019-03769-8 | by applicant | CA2439366 | WO03104236 | US8481546 | US9259389 | - AMIDON GL et al., "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", Pharm Res., (19950300), vol. 12, no. 3, pages 413 - 20, XP055640443 | - AMIDON GL et al., Pharm Res., (19950300), vol. 12, no. 3, pages 413 - 20 | - European Pharmacopeia Uniformity of Dosage Units 2.9.40, USP General Chapter <905> and Japanese Pharmacopeia 6.02 |